Your browser doesn't support javascript.
loading
Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine.
Babu, Tara M; Shen, Xiaoying; McClelland, R Scott; Wang, Zijun; Selke, Stacy; Wilkens, Chloe; Hauge, Kirsten A; McClurkan, Christopher L; Goecker, Erin; Laing, Kerry J; Koelle, David M; Greninger, Alexander L; Nussenzweig, Michel C; Montefiori, David C; Corey, Lawrence; Wald, Anna.
Afiliación
  • Babu TM; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Shen X; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
  • McClelland RS; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Wang Z; Department of Global Health, University of Washington, Washington, Seattle, USA.
  • Selke S; Department of Epidemiology, University of Washington, Seattle, Washington, USA.
  • Wilkens C; Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.
  • Hauge KA; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • McClurkan CL; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Goecker E; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Laing KJ; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Koelle DM; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Greninger AL; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Nussenzweig MC; Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
  • Montefiori DC; Department of Global Health, University of Washington, Washington, Seattle, USA.
  • Corey L; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
  • Wald A; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Open Forum Infect Dis ; 11(2): ofad673, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38379566
ABSTRACT
We evaluated the immunologic response to a novel vaccine regimen that included 2 doses of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent booster vaccine. A durable neutralizing antibody response to Omicron BA.4/BA.5 and BA.1 variants was observed at month 6 after the booster, while immune escape was noted for the XBB.1.5 variant.
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Open Forum Infect Dis Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Open Forum Infect Dis Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos